Weekly round-up #254

Hello from the Seminar

 

Watch Now - VALIDATE Seminar: A Double Bill with Institut Pasteur de Tunis

On 25 January, we held our first Seminar of 2023. Watch both talks on our YouTube Channel.

Targeting FOXO3 transcription factor as a Host-Directed approach to enhance the efficacy of
BCG against M.tb with Prof Makram Essafi

https://www.youtube.com/embed/N4XJi-OHjII

Here, Makram talks about his work on targeting the FOXO3 transcription factor as a host-directed approach to enhance the efficacy of BCG against Mycobacterium tuberculosis.

Vaccine against Human Leishmaniasis: Institut Pasteur de Tunis Contribution with 
Prof Dhafer Laouini – Watch now on YouTube

In this talk, Dhafer describes the efforts made by Institute Pasteur de Tunis’ scientists towards the development of a broadly protective anti-Leishmania vaccine.

 

 

Funding:

You can find a list of all relevant external funding we've spotted for our members on our external funding page.​​

Training Opportunities and Events:

​​​Find more event opportunities on our Training and Events pages.

Other relevant career opportunities are on our jobs page.

 

Publications:

Check out our Publications Page for members' publications and email VALIDATE@ndm.ox.ac.uk if you have a paper you would like us to include.

 

Highlights on Twitter this week:

 

News Medical shows that BCG does not protect the elderly from COVID-19, Precision Vaccines updated its list of TB vaccines for 2023, and Unite4TB promoted its Young Investigators Group. Kasturba Medical College is playing a leading role in India’s National Task Force for Melioidosis, te APHA in the UK is field testing bovine TB vaccines, and India plans to develop a new TB vaccine by 2025. Medpage reported more scepticism about BCG’s impact on COVID and GAVI reported on the positive economic impact of TB vaccines. Keep up to date with all the relevant news and opportunities by following @NetworkVALIDATE on Twitter.

 

Published: 8 February 2023